-SEC Filing
Replimune Presents Updated Data On RP2 In Uveal Melanoma During Plenary Session At The 20th International Congress Of The Society For Melanoma Research
Treatment with RP2 led to an overall response rate (ORR) of 29.4 percent (5 of 17 patients; one of the responding patients was treated with RP2 monotherapy and four of the responding patients were treated with RP2